ATF4 Targets RET for Degradation and is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer
- 9 December 2016
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 102 (3) , 933-941
Abstract
Article published by the Endocrine Society Article published by the Endocrine SocietyKeywords
This publication has 27 references indexed in Scilit:
- RET revisited: expanding the oncogenic portfolioNature Reviews Cancer, 2014
- Cabozantinib in Progressive Medullary Thyroid CancerJournal of Clinical Oncology, 2013
- Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cellsEMBO Molecular Medicine, 2013
- Vemurafenib Potently Induces Endoplasmic Reticulum Stress–Mediated Apoptosis in BRAFV600E Melanoma CellsScience Signaling, 2013
- ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine DeprivationCancer Cell, 2012
- KIF5B-RET fusions in lung adenocarcinomaNature Medicine, 2012
- High‐resolution analysis of alterations in medullary thyroid carcinoma genomesInternational Journal of Cancer, 2011
- Genome-Wide Copy Number Imbalances Identified in Familial and Sporadic Medullary Thyroid CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2003
- Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic miceOncogene, 2000
- Loss of heterozygosity on the long arm of chromosome 22 in pheochromocytomaGenes, Chromosomes and Cancer, 1992